In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on Talaris Therapeutics (TALS – Research Report), with a price target of $20.00. The company's shares closed last Monday at $6.96, close to its 52-week low of $5.70. According to TipRanks.com, Purohit is ranked 0 out of 5 stars with an average return of -25.3% and a 18.9% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Theravance Biopharma, and Foghorn Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Talaris Therapeutics with a $22.50 average price target, implying a 206.
https://www.tipranks.com/news/blurbs/morgan-stanley-thinks-talaris-therapeutics-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Talaris Therapeutics Charts.
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Talaris Therapeutics Charts.